AGT and triple-A syndrome: proved that AVE0991 reduced Ang II‐induced AAA formation in ApoE(−/−) mice by decreasing inflammation and oxidative stress, inhibiting MMP‐2 and ‐9 expression, downregulating P38 and ERK1/2 signaling pathways, and antiapoptosis of VSMCs.